EDMONTON, May 15, 2013 /CNW/ - Metabolomic Technologies Inc. (MTI), an
Alberta-based company that develops advanced metabolomic-based
diagnostic tests for chronic diseases, was recently named the recipient
of a Knowledge Translation Strategic Initiative Grant by Alberta
Innovates - Health Solutions (AIHS) in the amount of $375,000 through
the Alberta Cancer Prevention Legacy Fund (ACPLF).
"AIHS has an ambitious mandate to support Alberta's health research and
innovation priorities, and MTI has demonstrated the kind of high
quality activity that makes it an ideal recipient for this award," said
Dr. Pamela Valentine, Chief Operating Officer of AIHS. "Supporting
leading home-grown healthcare innovators like MTI is the key to our
mandate of improving the quality of life for Albertans."
Following on completion of MTI's 1,200 patient clinical trial, this new
funding will support validation trials for MTI's patented colonic polyp
(polyps can be precursors to colon cancer) screening diagnostics test: PolypDx™.
The AIHS funding will enable MTI to continue to work with Alberta Health
Services (AHS) to validate PolypDx™ in Lethbridge, Alberta. This is an
opportunity for an Alberta-based test to be developed in the province
and directly impact the health of Albertans. Currently, there are
approximately 300,000 Albertans who need to be screened for colon
MTI's PolypDx™ represents exciting next generation technology currently
This grant allows MTI to work directly with DynaLIFEDx to optimize this
test for large scale population screening. DynaLIFEDx, an Alberta-based
medical laboratory with global reach, has the capability to help MTI
accommodate large scale population screening of PolypDx™ in Alberta,
nationally and internationally.
"DynaLIFEDx is very pleased to be working with MTI to develop mainstream
clinical application for this technology. DynaLIFEDx is a proud partner
of the University of Alberta and AHS to actively drive the application
of new technology into mainstream healthcare delivery. MTI is a great
example of what is possible right here in Alberta. MTI is a success
story of technology developed in Alberta that will see Albertan's
benefit first," said Jason Pincock, Chief Executive Officer of
In addition to being a more attractive alternative to traditional cancer
screening tests, MTI's PolypDx™ demonstrates higher detection accuracy
than current fecal-based tests. The superior accuracy of MTI's
diagnostic tests will be a game-changer in the early detection and
prevention of colon cancer, which was responsible for 720 deaths in
Alberta last year (Colorectal Cancer Association of Canada, 2012).
"Typically, companies like MTI would need to explore international
partnerships to validate tests like PolypDx™. The successful launch of
these partnerships allows MTI the opportunity to collaborate with
Alberta partners in the early diagnosis of polyps and colon cancer,"
states MTI Chief Executive Officer Reg Joseph.
PolypDx™ was developed at the University of Alberta by AIHS funded
researcher Dr. Richard Fedorak, Dr. Haili Wang and their team at MTI, a
U of A spin-off company incorporated with the help of business
incubator TEC Edmonton.
Thanks to the Knowledge Translation Strategic Initiative Grant from
AIHS, MTI now has the means to conduct validation trials of PolypDx™
within "real-life" clinical environments.
For more information about MTI, visit www.metabolomictechnologies.ca.
About Metabolomic Technologies Inc.
Metabolomic Technologies Inc. (MTI) is a spin-off company from the
University of Alberta. The company was formed by Drs. Haili Wang and
Richard Fedorak to develop advanced metabolomic-based diagnostic tests
for the management of chronic diseases or 'high value' diagnostics.
MTI's initial focus is on developing highly novel, patented,
metabolomic-based diagnostic tests to detect adenomatous polyps and
colorectal cancer (CRC). Their flagship product, PolypDx™, a spot urine
diagnostic test, innovatively offers a significantly higher sensitivity
in detecting adenomatous polyps and thus significantly advances the
prevention of CRC. For more information, visit www.metabolomictechnologies.ca.
About Alberta Innovates - Health Solutions
Alberta Innovates - Health Solutions (AIHS) supports research and
innovation activities to improve the health and wellbeing of Albertans
and create, through innovation, health related social and economic
benefits for Albertans. It provides leadership for Alberta's health
research and innovation enterprise by directing, coordinating,
reviewing, funding and supporting research and innovation. For more
information, visit www.aihealthsolutions.ca.
The Alberta Cancer Prevention Legacy Fund aims to transform cancer
prevention for Albertans through innovative population based
initiatives, screening, and collaborative, focused research. Alberta
Health Services and AIHS work together to deliver on the Fund's mandate
under the strategic guidance of the Government of Alberta. Their
commitment is to an Alberta where most cancer is prevented.
SOURCE: Metabolomic Technologies Inc.
For further information:
Chief Executive Officer, MTI